Cargando…

PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma

BACKGROUND: The prevalence of programmed death-ligand 1 (PD-L1) and PD-L2 expression on tumor cells and tumor-infiltrating immune cells in primary central nervous system lymphoma (PCNSL) remains unclear. In the present study, we analyzed needle biopsy and craniotomy specimens of patients with PCNSL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Furuse, Motomasa, Kuwabara, Hiroko, Ikeda, Naokado, Hattori, Yasuhiko, Ichikawa, Tomotsugu, Kagawa, Naoki, Kikuta, Kenichiro, Tamai, Sho, Nakada, Mitsutoshi, Wakabayashi, Toshihiko, Wanibuchi, Masahiko, Kuroiwa, Toshihiko, Hirose, Yoshinobu, Miyatake, Shin-Ichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132991/ https://www.ncbi.nlm.nih.gov/pubmed/32248797 http://dx.doi.org/10.1186/s12885-020-06755-y

Ejemplares similares

ML-07 High expression of PD-L1 on tumor-associated macrophage is a predictive factor for favorable prognosis in PCNSL
por: Furuse, Motomasa, et al.
Publicado: (2020)

Intratumoral and peritumoral post-irradiation changes, but not viable tumor tissue, may respond to bevacizumab in previously irradiated meningiomas
por: Furuse, Motomasa, et al.
Publicado: (2015)

NI-04 WHICH RADIOLOGICAL IMAGING IS BEST TO DISCRIMINATE RADIATION NECROSIS FROM TUMOR PROGRESSION? - SUBANALYSIS OF SYSTEMATIC REVIEW FOR RADIOLOGICAL DIAGNOSIS OF RADIATION NECROSIS
por: Furuse, Motomasa, et al.
Publicado: (2019)

Characteristic and Management of Symptomatic Septum Pellucidum Cyst in Extreme Elderly Patient: Case Report and Literature Review
por: IKEDA, Naokado, et al.
Publicado: (2022)

Radiological diagnosis of brain radiation necrosis after cranial irradiation for brain tumor: a systematic review
por: Furuse, Motomasa, et al.
Publicado: (2019)

Frameless Stereotactic Biopsy with Intraoperative Computed Tomography “Assessment of Efficacy and Real Target Registration Error”
por: IKEDA, Naokado, et al.
Publicado: (2022)

Identification of early and distinct glioblastoma response patterns treated by boron neutron capture therapy not predicted by standard radiographic assessment using functional diffusion map
por: Hiramatsu, Ryo, et al.
Publicado: (2013)

Fluoroscopic-Guided Paramedian Approach for Lumbar Catheter Placement in Cerebrospinal Fluid Shunting: Assessment of Safety and Accuracy
por: Tucker, Adam, et al.
Publicado: (2019)

Long-Term Prognosis of Cognitive Function in Patients With Idiopathic Normal Pressure Hydrocephalus After Shunt Surgery
por: Kambara, Akihiro, et al.
Publicado: (2021)

Boron neutron capture therapy with bevacizumab may prolong the survival of recurrent malignant glioma patients: four cases
por: Miyatake, Shin-Ichi, et al.
Publicado: (2014)

The roles of platelet-derived growth factors and their receptors in brain radiation necrosis
por: Miyata, Tomo, et al.
Publicado: (2014)

Immunotherapy of Nivolumab with Dendritic Cell Vaccination Is Effective against Intractable Recurrent Primary Central Nervous System Lymphoma: A Case Report
por: FURUSE, Motomasa, et al.
Publicado: (2017)

Influence of surgical position and registration methods on clinical accuracy of navigation systems in brain tumor surgery
por: Furuse, Motomasa, et al.
Publicado: (2023)

Pathophysiology, Diagnosis, and Treatment of Radiation Necrosis in the Brain
por: MIYATAKE, Shin-Ichi, et al.
Publicado: (2015)

Inflammation as well as angiogenesis may participate in the pathophysiology of brain radiation necrosis
por: Yoritsune, Erina, et al.
Publicado: (2014)

Skull Bone Regeneration Using Chitosan–Siloxane Porous Hybrids—Long-Term Implantation
por: Shirosaki, Yuki, et al.
Publicado: (2018)

STMO-07 Adverse events related to the glioblastoma surgery and their perioperative management in our hospital
por: Kashiwagi, Hideki, et al.
Publicado: (2020)

ET-9 Development of photosensitive antibodies for near-infrared light immunotherapy targeting EGFR and IL13Rα2 of malignant gliomas and investigation of their photodynamic cytotoxic activity in vitro
por: Nonoguchi, Naosuke, et al.
Publicado: (2021)

Expression of PD-L1 on Canine Tumor Cells and Enhancement of IFN-γ Production from Tumor-Infiltrating Cells by PD-L1 Blockade
por: Maekawa, Naoya, et al.
Publicado: (2014)

Chronic pathophysiological changes in the normal brain parenchyma caused by radiotherapy accelerate glioma progression
por: Tsuji, Yuichiro, et al.
Publicado: (2021)

Preparation of Biphenyl-Conjugated Bromotyrosine for Inhibition of PD-1/PD-L1 Immune Checkpoint Interactions
por: Kim, Eun-Hye, et al.
Publicado: (2020)

Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1
por: Kuang, Dong-Ming, et al.
Publicado: (2009)

PD-L1 expression as a predictor of postoperative recurrence and the association between the PD-L1 expression and EGFR mutations in NSCLC
por: Kojima, Kensuke, et al.
Publicado: (2021)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Increase of cells expressing PD‐1 and PD‐L1 and enhancement of IFN‐γ production via PD‐1/PD‐L1 blockade in bovine mycoplasmosis
por: Goto, Shinya, et al.
Publicado: (2017)

Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma
por: Maekawa, Naoya, et al.
Publicado: (2016)

PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade
por: Ganbaatar, Otgontuya, et al.
Publicado: (2020)

PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma
por: Maekawa, Naoya, et al.
Publicado: (2021)

Transporter-Mediated Drug Interaction Strategy for 5-Aminolevulinic Acid (ALA)-Based Photodynamic Diagnosis of Malignant Brain Tumor: Molecular Design of ABCG2 Inhibitors
por: Ishikawa, Toshihisa, et al.
Publicado: (2011)

Chronic expanding pituitary hematoma with calcification resulting from pituitary adenoma: illustrative case
por: Takagi, Fugen, et al.
Publicado: (2023)

High‐affinity PD‐1 molecules deliver improved interaction with PD‐L1 and PD‐L2
por: Li, Yanyan, et al.
Publicado: (2018)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer
por: Jeong, Seri, et al.
Publicado: (2021)

Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
por: Shen, Xian, et al.
Publicado: (2018)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
por: Niu, Mengke, et al.
Publicado: (2022)

Regulation of Immunity in Clear Cell Renal Carcinoma: Role of PD-1, PD-L1, and PD-L2
por: Spirina, Liudmila, et al.
Publicado: (2021)

In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction
por: Lu, Chih-Hao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kmaof1tqnavihkbtcrd3fqtvug